• LAST PRICE
    1.1500
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-0.8621%)
  • Bid / Lots
    1.1500/ 17
  • Ask / Lots
    1.1600/ 8
  • Open / Previous Close
    1.1600 / 1.1600
  • Day Range
    Low 1.1400
    High 1.1700
  • 52 Week Range
    Low 1.0900
    High 6.2500
  • Volume
    46,534
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.16
TimeVolumeOCX
09:32 ET54421.14
09:34 ET2001.16
09:36 ET9101.16
09:38 ET4001.16
09:39 ET15931.17
09:41 ET248031.17
09:43 ET86061.15
09:45 ET2001.15
09:48 ET10861.15
09:50 ET5001.15
09:52 ET5001.15
09:54 ET1001.15
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOCX
OncoCyte Corp
129.2M
-1.5x
---
United StatesHGEN
Humanigen Inc
130.0M
-0.6x
---
United StatesADAG
Adagene Inc
137.8M
-1.7x
---
United StatesATHX
Athersys Inc
139.4M
-1.9x
---
United StatesIMRX
Immuneering Corp
133.2M
-2.9x
---
United StatesARMP
Armata Pharmaceuticals Inc
116.8M
-4.3x
---
As of 2022-05-17

Company Information

OncoCyte Corporation is a molecular diagnostics company. The Company is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

Contact Information

Headquarters
15 CUSHINGIRVINE, CA, United States 92618
Phone
949-409-7600
Fax
510-521-3389

Executives

Independent Chairman of the Board
Andrew Arno
President, Chief Executive Officer, Director
Ronald Andrews
Corporate Development Officer
Mitchell Levine
Chief Operating Officer
Gisela Paulsen
Principal Accounting Officer, Vice President, Controller
Li Yu

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$129.2M
Revenue (TTM)
$8.0M
Shares Outstanding
118.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.86
EPS
$-0.77
Book Value
$0.71
P/E Ratio
-1.5x
Price/Sales (TTM)
16.1
Price/Cash Flow (TTM)
---
Operating Margin
-891.95%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.